Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

nger patients. In the Phase 1 trial, voreloxin was administered on a weekly or twice-weekly schedule and patient demographics were similar between the two treatment schedules. Six patients, including four age 60 or older and two younger than age 60, achieved complete remission (CR) or complete remission without platelet recovery (CRp) or complete remission with incomplete recovery of hematopoeitic elements (CRi) when voreloxin was administered at doses of 50 mg/m2 or greater weekly or 40 mg/m2 twice-weekly. Duration of complete remissions (CR or CRp) was reported. Remissions of up to seven months have been observed thus far, with two patients undergoing reinduction with voreloxin following relapse.

Sixty-eight patients were evaluable for safety, with 42 patients ranging in age from 60-85 years old and 26 patients age 21-59 years. Voreloxin was generally well tolerated in both the older and younger patient subgroups with similar incidence of Grade 3-4 adverse events. The dose-limiting toxicity was reversible oral mucositis, and a maximum-tolerated dose of 72 mg/m2 once-weekly and 40 mg/m2 twice-weekly was established. Researchers also reported that voreloxin pharmacokinetics were not influenced by age.

"AML is primarily a disease of the elderly and the medical need for new agents that can be tolerated by older patients remains unmet. Results from our comparative analysis demonstrate that voreloxin is generally well tolerated and achieves anti-leukemic activity among older, advanced AML patients, supporting our strategy for progressing the clinical development of voreloxin in this indication," said Glenn Michelson, M.D., Vice President, Clinical Strategy at Sunesis. "Sunesis recently initiated the Phase 2 REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) clinical trial to evaluate voreloxin in newly diagnosed AML in elderly patients. We hope to present initial data from the REVEAL-1 trial later this year."

Preliminary Data from Phase 1b S
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... THOUSAND OAKS, Calif. , Jan. 22, 2015  Amgen (NASDAQ: ... quarter and full year 2014 financial results on Tuesday, Jan. 27, ... will be followed by a conference call with the investment community ... be Robert A. Bradway , chairman and chief executive officer, ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... The Pharmaceutical Care Management Association (PCMA) issued the ... hearing: "The independent drugstore lobby continues ... for themselves in Medicaid while demanding more transparency for ... and retail pharmacy allies in the embarrassing role of ...
... Oxford Finance Corporation (Oxford), a subsidiary of ... Debbie Baker to its Business Development group. As director, ... for life science and medical device companies, primarily in ... 30 years of financial experience, predominantly with the healthcare ...
Cached Medicine Technology:PCMA: Independent Drugstore Lobby Continues 'Disclosure Double Standard' Transparency Campaign 2Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... and Awareness for ... Generation Rescue, WEST ... and Joely Fisher to celebrate the launch of,TotSpot.com ( http://www.totspot.com ) ... Harvard graduates Michael Broukhim and,Adam Katz, TotSpot.com is the world,s first ...
... Nov. 9-15, DENVER, Nov. 10 Students at ... can bring their beloved teddy,bears and other tattered toys ... and bandage them today, teaching students a unique,lesson about ... the Association of the Perioperative Registered Nurses (AORN),Perioperative Nurse ...
... Dr. James Cook, president of,the American Veterinary Medical ... -- treating pets that have become sick due to,holiday ... Years, we,ll see it,every year at my practice, and, ... "People want to involve their pets in the,holiday celebrations, ...
... early tenure turnover costs. , ... Washington, DC (PRWEB) ... workforce planning, reporting and analytics solutions, today released a case study ... workforce analytics program. Through in-depth analysis of workforce data, WellPoint ...
... Studio, an Eclipse plug-in, improve HP OpenVMS productivity without specialized skills ... ... Systems, a leader in legacy systems evolution, today announced new additions ... Studio for the HP OpenVMS platform., , ,The products, marketed jointly ...
... with Bachelor,s Degrees , ... Houston, TX (PRWEB) November 10, 2008 -- ... recently voted to reopen the Nursing School to help ease ... operated from 1972 to 1986, when a faltering economy caused the school ...
Cached Medicine News:Health News:TotSpot.com Celebrates Launch With Jenny McCarthy, Joely Fisher, Tori Spelling and Other Celebrity Mommies at The Treehouse Social Club 2Health News:Teddy Bear Hospital Helps Ease Kids' Anxieties About Surgery 2Health News:AVMA's Top Ten List on Holiday Pet Health 2Health News:Infohrm Member Client Saves Millions of Dollars Through Workforce Analytics 2Health News:Infohrm Member Client Saves Millions of Dollars Through Workforce Analytics 3Health News:eCube Systems Brings Remote Eclipse Development to HP OpenVMS 2Health News:eCube Systems Brings Remote Eclipse Development to HP OpenVMS 3Health News:University of St. Thomas Houston to Reopen Nursing School 2
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Ultraview SL 3800...
Medicine Products: